title: [Homocysteine and cardiovascular disease].
abstract: Treatment of highly increased plasma concentrations of homocysteine in patients with rare inborn errors of metabolism reduces their risk of vascular thromboses. Many, but not all, epidemiological studies show a relation between slightly increased plasma homocysteine and ischaemic cardiovascular disease. Folic acid supplements reduce plasma homocysteine. The results of ongoing studies of the effect of folic acid and other vitamins on the incidence of cardiovascular disease are expected within the next five years. The available data support the measurement of plasma homocysteine as a part of screening of patients with early and/or frequent vascular thromboses and a disparity between established risk factors and symptoms. Plasma homocysteine > 30 mumol/l in such patients should prompt a search for an inborn error of metabolism.
authors: H:S Rigshospitalet, klinisk genetisk afdeling.
authors: F
authors: F
authors: Skovby
authors: J
authors: J
authors: Dyerberg
authors: E
authors: E
authors: Nexø
authors: M
authors: M
authors: Osler
authors: K
authors: K
authors: Rasmussen
authors: S
authors: S
authors: Stender
mesh_terms: D000592:Amino Acid Metabolism, Inborn Errors / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D015415:Biomarkers / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood / Q000209:etiology; D016017:Odds Ratio; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D006710:Homocysteine